Arthur Snyder, MD
Rheumatology · Las Cruces, NMNPI 1629079710
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 500 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Amgen at 33.8% of the total. Reporting peaked in 2019 at $2,363 and has fallen 95.3% since, to $111 in 2025. Among rheumatology clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 500 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AbbVie$2K
- Pfizer$865
- UCB, Inc.$521
- AstraZeneca$464
- GSK$353
- plus $2K from 15 others
Across 273 payments — averaging $5506.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$908K
- Astrazeneca UK Limited$235K
- Novartis$208K
- Eli Lilly$79K
- GSK$72K
- E.r. Squibb & Sons, L.L.C.$523
What the payments were for
- Food & beverage$8,22996%
- Education$3374%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 138 | $2,894 |
| AbbVie | 109 | $1,804 |
| Pfizer | 87 | $865 |
| UCB, Inc. | 34 | $521 |
| AstraZeneca(2 entities) | 25 | $464 |
| GSK | 18 | $353 |
| Novartis | 16 | $292 |
| Johnson & Johnson(2 entities) | 18 | $287 |
| Radius Health, Inc. | 12 | $247 |
| Aurinia Pharma U.S., Inc. | 8 | $175 |
| E.r. Squibb & Sons, L.L.C. | 8 | $154 |
| Boehringer Ingelheim | 4 | $90 |
| Mallinckrodt Enterprises LLC | 3 | $83 |
| Fresenius Kabi USA, LLC | 4 | $75 |
| Bristol Myers Squibb | 5 | $64 |
| Genentech USA, Inc. | 4 | $61 |
| Sanofi | 2 | $47 |
| Actelion Pharmaceuticals US, Inc. | 2 | $32 |
| Organon | 1 | $24 |
| Sandoz | 1 | $21 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$123
How this compares
$8,565 in reported general payments places this provider in the 90th percentile of 44 rheumatology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 100 | $1,334,311 |
| RinvoqUpadacitinib | 152 | $1,164,099 |
| Enbrel SureclickEtanercept | 43 | $614,348 |
| Xeljanz XrTofacitinib Citrate | 84 | $497,487 |
| Enbrel MiniEtanercept | 50 | $400,963 |
| OrenciaAbatacept | 21 | $211,331 |
| XeljanzTofacitinib Citrate | 20 | $207,545 |
| Orencia ClickjectAbatacept | 22 | $202,754 |
| OtezlaApremilast | 30 | $187,073 |
| LupkynisVoclosporin | 11 | $163,010 |
| BenlystaBelimumab | 19 | $89,029 |
| Humira PenAdalimumab | 11 | $73,580 |
| Actemra ActpenTocilizumab | 13 | $62,307 |
| Cevimeline Hcl | 83 | $21,056 |
| Mycophenolate Mofetil | 159 | $19,998 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Restasis | $1,804 | $1,175,742167 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $154 | $211,33121 claims |
| PfizerXeljanz | $865 | $207,54520 claims |
| AmgenOtezla | $2,894 | $187,07330 claims |
| Aurinia Pharma U.S., Inc.Lupkynis | $175 | $163,01011 claims |
| GSKBenlysta | $353 | $89,02919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 44 rheumatology providers in New Mexico.
Other rheumatology in Las Cruces
- Chinenye OsuorjiLas Cruces$112
- Hillary NortonSanta Fe$1.9M
- Ahmad RamahiRoswell$35K
- Adrian Michaella Mesilla$16K
- Wilmer SibbittAlbuquerque$9K
- Leroy PachecoAlbuquerque$8K
- Albert RizzoliAlbuquerque$7K
- Susan BarrettSanta Fe$7K
- Jayashree SinhaClovis$7K
- Scott StoernerAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.